Results of the Search
The initial search identified 307 articles (see Fig. 1). After removing duplicate articles, 213 remained for the first evaluation. Following review of the title, abstract and keywords of these records, 12 candidate articles were identified that met the predefined criteria, and full-text versions were obtained for further review. Four candidate articles did not meet the review inclusion criteria and were therefore rejected, leaving eight eligible articles for appraisal [5–12]. Examination of the full-text version of these articles and their bibliographies identified three additional eligible articles [13–15]. A total of 11 articles were included in the final analysis.
Description of Included Studies
The 11 studies reviewed can be separated into those comparing the frequency of genotypes or alleles between two groups (case–control) (Table 2) [6, 15]; cohort studies where participants were separated according to task success or failure and where genotype or allele frequencies were compared between groups (Table 3) [8–10]; and cohort studies comparing the difference in performance measures (continuous variable) between individuals grouped by genotype or allele (Table 4) [6, 7, 11, 12]. Two studies used a different approach, and examined whether Spanish compared with Quechua genetic admixture explained differences in \( \dot{V} \)O2max at high altitude [13, 14]. According to the location of the corresponding author, studies were from the UK (n = 4), the USA (n = 3), Greece (n = 1), New Zealand (n = 1), South Africa (n = 1), and China (n = 1). The number of subjects in each study varied from 20 to 1,931, and consisted of healthy males in four studies [12–15] and healthy males and females in six studies [5, 7–11], with sex of the participants not stated in one study [6]. The maximum altitude of exposure ranged from 2,690 to 8,848 m. The exercise performance phenotype assessed was mountaineering performance in five studies [6, 8–10, 15], running performance in two studies [7, 11] and maximum oxygen consumption in four studies [5, 12–14]. In total, 13 genetic polymorphisms located within ten different genes were studied, excluding those used to estimate genetic admixture by Brutsaert and colleagues [13, 14]. The most studied gene was that encoding the angiotensin I-converting enzyme (ACE), which was studied in seven separate papers. The names of all the genes studied, excluding those used to indicate Quechua and Spanish ancestry by Brusaert and co-workers [13, 14], are listed in Table 5 along with the symbols and the chromosomal location. Results are presented according to the genetic polymorphism of interest, then by phenotype of interest (given sub-heading where necessary), and are ordered based on the maximum altitude studied.
Table 2 Exercise performance in atmospheric hypoxia and candidate genes; case-control studies
Table 3 Exercise performance in atmospheric hypoxia and candidate genes: cohort studies separated by summit success
Table 4 Exercise performance in atmospheric hypoxia and candidate genes: cohort studies studying a continuous trait
Table 5 Symbols, names, and chromosomal location of all genes identified
Angiotensin-Converting Enzyme (ACE) Insertion/Deletion (I/D) Polymorphism (rs4646994)
Seven studies investigated the association of the ACE I/D (rs4646994) polymorphism with exercise performance at altitude. Two were case–controlled studies that compared genotype or allele frequencies between high-altitude mountaineers and a control population (Table 2). Five cohort studies were also conducted; in three of these, study participants were separated according to task success or failure, and genotype and/or allele frequencies were compared between groups (Table 3), whilst two studies compared performance phenotype (as a continuous variable [e.g. time and \( \dot{V} \)O2max]) between those of different genotype (Table 4).
Mountaineering Performance
In a prospective study, Tsianos et al. [10] reported the ACE I-allele to be associated with successful ascent of Mont Blanc (4,807 m). ACE genotype distribution varied between Caucasian climbers who successfully summited Mt Blanc (n = 183) and those who tried and failed (n = 12) (p = 0.048) (OR 3.41), the I allele being more prevalent in those who summited than in those who did not (0.47 vs 0.21, p = 0.01) (Table 3). The proportion of those of each genotype who successfully summited was 87.7, 94.9 and 100 % for the DD, ID, and II genotypes, respectively.
Kalson et al. [8] prospectively studied Caucasian trekkers attempting to climb Mt Kilimanjaro (5,895 m), participants being separated by ascent rate (4 days [‘direct’] vs. 5 days [‘slow’]). Genotype distribution did not differ by success rate in the ‘slow’ group (II: 9 [0.22], ID: 18 [0.44], DD: 14 [0.34] successful versus II: 9 [0.22], ID: 22 [0.54], DD: 10 [0.24] unsuccessful, p = 0.54; I allele frequency 0.44 vs. 0.49, respectively; OR 0.82). In ‘fast ascent’ subjects, ACE genotype distribution was II: 6 (0.30) vs. ID: 11 (0.55) vs. DD: 3 (0.15) in those who were successful and II: 0 (0.00) vs. ID: 10 (0.71) vs. DD: 4 (0.29) in those who failed (p = 0.09). I-allele frequency for those who were successful versus those who failed was 0.58 vs. 0.36 (OR 2.44) (Table 3).
Montgomery et al. [15] studied ACE genotype in 25 elite British high-altitude mountaineers who had frequently ascended beyond 7,000 m without supplementary oxygen. When compared with 1,906 British controls (free from clinical cardiovascular disease), the I allele was found to be over-represented in cases (p = 0.003), as was the ACE II genotype (proportion 0.48 vs. 0.23 in cases vs. controls, respectively) (OR 2.43) (Table 2). The DD genotype was not present in any individual who had previously ascended beyond 8,000 m.
Djarova et al. [6] also reported I allele prevalence to be greater in five elite Bulgarian mountaineers (all climbed above 7,500 m without supplementary oxygen) than in 72 Bulgarian student controls (0.60 vs. 0.41, respectively; p = 0.002) (OR 2.29). ACE genotype distribution differed, largely due to an excess of ID genotype in the elite group (p = 0.024) (Table 2). The small case population (n = 5) limits confidence in this finding. Further, we were unable to replicate their statistical analysis: using the ACE allele frequencies and population numbers stated in the paper, and applying Fisher’s exact test (as the authors did) in a commonly used statistical package (SPSS 21 [IBM, Armonk, NY, USA]), we were unable to demonstrate a statistically significant difference in ACE allele frequencies between the two groups (p = 0.203). The same held true for the two other polymorphisms they studied, which were the alpha actinin-3 ACTN3 R577X (rs1815739) and the adenosine monophosphate deaminase (AMPD1) C34T polymorphisms (rs17602729).
Thompson et al. [9] extended the observations of Tsianos et al. [10], Kalson et al. [8] and Montgomery et al. [15] to individuals attempting to climb beyond 8,000 m, also noting the maximum altitude attained by each individual and the reason for failure. Once again, in a population of Caucasian and Asian mountaineers, ACE genotype distribution differed between successful summiteers (n = 92) and those who failed (n = 57) (OR 2.15) (Table 3) (p = 0.003). Both II genotype and the I allele were more prevalent in the successful group (II genotype 0.33 vs. 0.06 [p = 0.003]; I allele, 0.55 vs. 0.36 for success vs failure, respectively). Maximum altitude attained (as a continuous variable) was also related to ACE I allele, being 8,079 vs. 8,107 and 8,559 m for those of DD, ID and II genotype, respectively (allele comparison, p = 0.0023).
Maximum Oxygen Uptake (\( \dot{V} \)O2max) at Altitude
Bigham et al. [5] reported the relationship of ACE genotype with \( \dot{V} \)O2max at 4,338 m in Peruvian high-altitude native residents (n = 74) and in Peruvian low-altitude residents whose family originate from high altitude (n = 68). \( \dot{V} \)O2max did not differ by genotype, even when other cofactors, such as altitude of residence, were accounted for (Table 4).
Sea-Level Running Performance
Hinckson et al. [7] studied whether improvement in sea-level exercise performance following hypoxic exposure (2,500–3,500 m) was related to ACE genotype (Table 4). This study was primarily designed to test the efficacy of hypoxic training for improving running performance. It included a study group whose ten participants were exposed to 4 weeks of hypoxia for >10 h per day, and ten controls who had no hypoxic exposure. In eight participants (ethnicity not disclosed) in the study group, the relationship between improvements in running performance following hypoxic training with ACE I/D genotype was sought (Table 3). However, neither numerical results by genotype nor statistical analysis are reported—although a figure suggests a lack of genotype association.
ACTN3 R577X (rs1815739)
Two studies tested whether an association was present between the ACTN3 R577X polymorphism and high-altitude exercise performance. Tsianos et al. [11] included the ACTN3 RX polymorphism as one of 11 polymorphisms (in eight genes) for which an association was sought with performance in the Mt Olympus Marathon (maximum altitude of 2,690 m). In all, no such association was identified in 438 participants over 2 years of racing. The distribution of the ACTN genotypes in the small elite high-altitude mountaineer cohort (n = 5) tested by Djarova et al. [6] was RR 1 (0.20), RX 3 (0.60), and XX 1 (0.20) compared with RR 30 (0.42), RX 32 (0.44) and XX 10 (0.14) in the control group (n = 72). The allele frequencies between the two groups were different (p = 0.032), with a relative excess of the X allele in the mountaineers (OR 1.77) (Table 2). However, as discussed in the previous section, the statistical approach of Djarova et al. [6] was of questionable validity. Using the allele frequencies and subject numbers from the paper [6], we found no difference in the ACTN RX allele distributions between the two populations (p = 0.501).
AMPD1 C34T (rs17602729)
In the study by Tsianos et al. [11] (see previous section), the AMPD C34T polymorphism was not associated with Mt Olympus Marathon performance for the whole group studied, but subgroup analysis revealed a modest association between the T allele (referred to as the ‘A allele’ in Tsianos et al. [11]) and better performance in athletes whose preferred sport was running (event completion time, p = 0.021; best ever time, p = 0.03). Djarova et al. [6] found that the frequency of the T allele was higher in mountaineers than in controls (p = 0.032; OR 2.82) (Table 2). However, as stated in the previous two results sections, the statistical analysis in this study is incorrect; using the reported allele frequencies in a Fisher’s test, we found no difference in the distribution of the allele of the AMPD1 C34T polymorphism between the elite mountaineers and controls (p = 0.155).
Other Polymorphisms
Ten other polymorphisms were studied. Of nine studied by Tsianos et al. [11] (listed in Table 4), the beta2-adrenergic receptor (ADRB2) Gly16Arg single nucleotide polymorphism (SNP) (rs1042713) was associated with performance in the Mt Olympus Marathon. In the study by Tsianos et al. [11], the Arg allele was associated with a shorter time to complete the race amongst people who chose running as their preferred exercise mode (p = 0.015), and with best ever Mt Olympus Marathon time for those who had completed the event multiple times (p = 0.003). Meanwhile, Wang et al. [12] studied the association between the androgen receptor (AR) CAG repeat polymorphism and \( \dot{V} \)O2max changes in 65 unrelated Han Chinese college athletes following a 30-day bout of intermittent hypoxic exposure, consisting of 10 h a day of sleeping at 14.8–14.3 % O2 (simulating 2,800–3,000 m altitude), 30-minute exercise bouts at 15.4 % O2 (simulating 2,500 m altitude) three times per week, and additional sea-level training. They found that individuals with the lowest number of CAG repeat units (≤21) had a greater increase in \( \dot{V} \)O2max following hypoxic training than those with a higher number of repeats (>21) (∆\( \dot{V} \)O2max; ≤21 CAG repeats 11.9 % increase, >21 CAG repeats 3.6 % increase; p = 0.004).
High-Altitude Population Ancestry
Two papers from the same group measured a number of physiological variables, including \( \dot{V} \)O2max, at altitude in Peruvian males of mixed Quechua and Spanish origins [13, 14]. Both sought to determine whether individuals with stronger Quechua (historical long-term high-altitude resident) origins had favourable physiological responses to altitude. We considered excluding these two papers as, strictly speaking, they do not meet one of the inclusion criteria: to ‘seek to identify genetic factors.’ However, we did include them given that they studied exercise performance at altitude and separated individuals based on their genetic profile. The first, published in 2004, comprised two groups from Peru; a group resident in Lima (sea level) and a group resident in Cerro de Pasco (4,388 m) [13]. No association was found between \( \dot{V} \)O2max values at an altitude of 4,388 m, and the degree of Quechua, Spanish and African ancestry, as indicated by 22 genetic markers. The second study [14] used the same lowland population and the same genetic profiling as the 2004 study [13] (confirmed with primary author of the manuscripts via email correspondence) and analysed the influence of genetic admixture on the magnitude of the \( \dot{V} \)O2max decrement from sea level to high altitude (data not presented in the same author’s 2004 paper). After controlling for other covariates, genetic admixture explained a significant proportion of the variation (β −0.205) in the decrement in \( \dot{V} \)O2max from sea level to high altitude (p = 0.041), with those with a higher Quechua (and lower Spanish) genetic ancestry maintaining sea-level \( \dot{V} \)O2max values to a greater degree.
Study Quality
As the method of assessing study quality is not validated and may only provide a guide to the quality of reporting of the research, we have not commented on each study individually. Instead, we aim to identify trends in the available literature where the conduct and/or reporting of research could be improved. The median score achieved in the study quality analysis was 6 out of 10 for case–control studies, 8 out of 10 for cohort studies with a discrete outcome, 6 out of 9 for cohort studies with a continuous outcome, and 4.5 out of 8 for genetic admixture studies (Table 6). The study quality score ranged considerably between studies, for example in cohort studies with a continuous outcome the total score ranged from 2 to 7 out of 9.
Table 6 Study quality results
In the case–control studies, the descriptions of the case groups were adequate, with both the studies given a score of 1 [6, 15]. However, only one of the control groups was deemed adequate [15], with the other study failing to provide adequate information about whether the level of relatedness of participants was controlled [6]. The majority of studies in which testing for Hardy–Weinberg (HW) equilibrium was appropriate did so (seven of eight). The one study that did not test for HW equilibrium had very small subject numbers (n = 8) and so it would have provided very little information [7]. In the other three studies, two investigated whether genetic admixture was associated with performance. This approach utilised polymorphisms that differed according to ancestry, meaning that testing for HW equilibrium would be uninformative [13, 14]. In the other study, the polymorphism was located on the X chromosome, and the populations were male, so genotype distribution would not conform with HW equilibrium, evidence of which was thus not sought [12].
Three study quality criteria relate to genotyping methods and reporting: providing the sequence of primers, demonstrating the reproducibility of the genotyping methods, and adequately blinding the genotyping staff from the phenotype details. Most studies (7 of 11) provided the details of the primer sequence (or a reference to them), one stated that this would be made available on request [11], two gave reference to a website that could be used to identify them [13, 14], and one failed to provide any information [7]. Eight studies stated that they had validated their genotyping methods or cited a reference for a validation study, while only two studies stated that their genotyping staff were blinded from the phenotype data.
The statistical merit of each paper was analysed in three of the study quality criteria. These analysed whether appropriate statistical tests were performed, whether adjustments were made to account for multiple comparisons in studies analysing more than one polymorphism, and whether power calculations were made. Ten of the 11 studies used appropriate formal methods of comparison to establish whether difference were present between groups. Only one study did not use a formal test of significance, and this was probably justified because the small number of participants would have precluded any meaningful results being obtained [7]. Only one study analysed several polymorphisms and failed to make adjustments for multiple comparisons [6]. Four of the 11 studies conducted sample size calculations [6, 8, 11, 13], with one study performing the calculation prior to conducting the study [11].
No article included in the review provided both a study identifying a potential polymorphism and a study validating the original finding. Following the original paper analysing the association between the ACE I/D polymorphism and mountaineering performance by Montgomery et al. [15], several other papers analysed the association between this polymorphism and highly related phenotypes [6, 8–10]. Furthermore, one study replicated polymorphisms related to endurance performance at sea level using an endurance race at altitude as the phenotype [11].